Targeting SEC23A: Artesunate's dual pathway approach to reversing gastric metaplasia
Journal of Pharmaceutical Analysis · 2026-10 · 16 (10) · 101667
DOI: 10.1016/j.jpha.2026.101667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-10. Verfasst von Qichao Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University of Trad…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Artesunate (ART) is a promising multi-target drug, yet its efficacy and mechanism against intestinal metaplasia (IM)/spasmolytic polypeptide-expressing metaplasia (SPEM), a key precancerous gastric lesion with no effective therapy, remain unexplored. This work presented that ART reversed SPEM and IM progression in mice, selectively impairing IM cell viability via inducing paraptosis. Mechanistically, ART triggered paraptosis through dual pathways, involving reactive oxygen species (ROS)-dependent c-Jun N-terminal kinase (JNK)/P38 mitogen-activated protein kinase (MAPK) activation and ROS-independent endoplasmic reticulum (ER) stress via direct SEC23 homolog A (SEC23A) binding. ART disrupted SEC23A-SEC24 homolog A (SEC24A) dimer formation, inducing ER stress via promoting K63-linked ubiquitination and P62-mediated autophagic degradation of SEC23A. Moreover, its efficacy was confirmed in human-derived IM organoids, showing reduced growth, SEC23A degradation, and MAPK/ER stress activation. Taken together, ART alleviates gastric precancerous lesions by selectively inducing paraptosis through ROS-dependent JNK/P38 MAPK activation and SEC23A-targeted ER stress via coatomer protein complex II (COPII) disruption and autophagic degradation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chinese Medicine Germplasm Resources Innovation and Effective Uses Key Laboratory of Sichuan Province, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
- Key Laboratory of Standardization of Chinese Medicine (Chengdu University of Traditional Chinese Medicine), Ministry of Education, Chengdu, 611137, China.
- TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
- School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
- Data Science Institute, University of Technology Sydney, NSW, 2007, Australia.
- Department of Pharmacy, The Fifth Medical Center of the PLA General Hospital, Beijing, 100039, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Hu, Q., Wu, F., Zhang, Y., Zeng, L., Chen, J., Ma, Y., Ma, X., Zeng, J., & Zhao, Y. (2026). Targeting SEC23A: Artesunate's dual pathway approach to reversing gastric metaplasia. Journal of Pharmaceutical Analysis, 16(10), 101667. https://doi.org/10.1016/j.jpha.2026.101667
Vancouver
Hu Q, Wu F, Zhang Y, Zeng L, Chen J, Ma Y, et al. Targeting SEC23A: Artesunate's dual pathway approach to reversing gastric metaplasia. Journal of Pharmaceutical Analysis. 2026;16(10):101667. doi:10.1016/j.jpha.2026.101667
BibTeX
@article{Hu2026,
author = {Hu, Qichao and Wu, Feng and Zhang, Yuanhao and Zeng, Lingshun and Chen, Jie and Ma, Yemei and Ma, Xiao and Zeng, Jinhao and Zhao, Yanling},
title = {Targeting SEC23A: Artesunate's dual pathway approach to reversing gastric metaplasia},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
volume = {16},
number = {10},
pages = {101667},
doi = {10.1016/j.jpha.2026.101667}
}
EUVIMED